First PARP inhibitor approved in Japan to demonstrate clinically meaningful benefits in combination with a new hormonal agent
ZN-A-1041 was designed to be blood-brain-barrier-penetrant, and has the potential to treat or prevent the onset of brain metastases in patients with HER2-positive metastatic breast cancer
The Research by Indian Fellow at the University has major implications for neurodegenerative disease treatments
The OCEANIC program will start with two Phase III studies investigating the efficacy and safety of asundexian in prevention of stroke
The abstract is about the cohort A, stage I of the ongoing global phase ? trial that evaluating the safety and efficacy of Catumaxomab in advanced GC patients with peritoneal metastasis
Novel approach driven by GN Corp Japan with potentials in neurological illnesses
New results build on previously reported significant recurrence-free survival (rfs) benefit seen in these patients
FortePhest is developing a new technology to combat herbicide-resistant weeds and invasive plants
The release of this batch will secure the supply for hospitals and cancer centres that are involved in the clinical trials managed by the company
The new products include the COAG Line automated, semi-automated and POC systems manufactured by Diagon Hungary
Subscribe To Our Newsletter & Stay Updated
